We identified three common signature genes (PLCXD3, CCL19, and PKD2), co-regulated pathways, and shared immune features of advanced NAFLD and AS, and then established effective diagnosis models. This evidence concerns the gene CCL19 and metabolic dysfunction-associated steatotic liver disease.